Collegium Pharmaceutical Inc (OQ:COLL)

Business Focus: Pharmaceuticals

Apr 11, 2024 08:00 am ET
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all...
Apr 03, 2024 08:00 am ET
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside...
Feb 22, 2024 04:09 pm ET
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and...
Feb 08, 2024 08:00 am ET
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and...
Jan 03, 2024 08:00 am ET
Collegium Provides 2024 Financial Guidance
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced its 2024 full-year financial guidance and provided a business update. “2023 was a banner year for Collegium. We are on track to...
Nov 27, 2023 08:00 am ET
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in...
Nov 09, 2023 08:00 am ET
Collegium Announces $25 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share...
Nov 08, 2023 08:00 am ET
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the...
Nov 07, 2023 04:01 pm ET
Collegium Reports Third Quarter 2023 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter ended...
Oct 24, 2023 08:00 am ET
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2023...
Aug 28, 2023 08:00 am ET
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that 10 poster presentations highlighting data...
Aug 24, 2023 08:00 am ET
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration...
Aug 07, 2023 07:30 am ET
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share...
Aug 03, 2023 04:01 pm ET
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter ended...
Jul 20, 2023 08:00 am ET
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2023...
Jun 01, 2023 08:00 am ET
Collegium to Participate in Jefferies Healthcare Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside...
May 04, 2023 04:01 pm ET
Collegium Reports First Quarter 2023 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter ended...
Apr 20, 2023 08:00 am ET
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023...
Apr 11, 2023 08:00 am ET
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside...
Feb 23, 2023 04:01 pm ET
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and...
Feb 22, 2023 08:00 am ET
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance (ESG) report. The report reflects the Company’s long-standing...
Feb 07, 2023 09:54 pm ET
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers...
Feb 06, 2023 04:08 pm ET
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to...
Feb 06, 2023 04:07 pm ET
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a...
Jan 04, 2023 08:00 am ET
Collegium Provides 2023 Financial Guidance
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced its 2023 full-year financial guidance and provided a business update. “2022 was a pivotal year for Collegium. We achieved the...
Dec 22, 2022 08:00 am ET
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of the U.S. District Court for the District of Delaware that certain claims of...
Nov 22, 2022 08:00 am ET
Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held in New...
Nov 03, 2022 04:01 pm ET
Collegium Reports Third Quarter 2022 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today reported its financial results for the quarter ended September 30, 2022 and provided a corporate update. “We made significant progress in...
Oct 20, 2022 08:00 am ET
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third quarter 2022 financial results after the market closes on Thursday, November 3, 2022. Following the...
Aug 30, 2022 08:00 am ET
Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentations highlighting data regarding its product portfolio will be presented at the Annual PAINWeek National...
Aug 04, 2022 04:01 pm ET
Collegium Reports Second Quarter 2022 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update. “Following closing of the...
Jul 21, 2022 08:00 am ET
Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. Following the...
May 17, 2022 08:00 am ET
Collegium to Participate in H.C. Wainwright Global Investment Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach...
May 10, 2022 04:01 pm ET
Collegium Reports First Quarter 2022 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the first quarter 2022 and provided a corporate update. “2022 is a pivotal year for Collegium, and we made excellent progress in the quarter versus our...
Apr 26, 2022 04:00 pm ET
Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET. The Company will...
Apr 07, 2022 04:47 pm ET
Collegium to Participate in Upcoming Needham Healthcare Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in the following investor conference: 21st Annual Needham Virtual Healthcare ConferenceVirtual...
Apr 06, 2022 08:00 am ET
Collegium Appoints Neil McFarlane to its Board of Directors
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. “Collegium is delighted to welcome...
Apr 05, 2022 08:00 am ET
Collegium Provides 2022 Financial Guidance
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced updated financial guidance for the full year 2022 to include the expected impact of the BioDelivery Sciences International Inc....
Mar 30, 2022 08:01 am ET
Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United...
Mar 22, 2022 05:01 pm ET
Collegium Completes the Acquisition of BDSI
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in our mission to build...
Feb 24, 2022 04:01 pm ET
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and full-year 2021 and provided a corporate update. “We strengthened the fundamentals of our pain portfolio in the face of challenging market...
Feb 16, 2022 09:50 pm ET
BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences Internationa
NEW ORLEANS, Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of BioDelivery Sciences International, Inc. (NasdaqGS: BDSI) to Collegium Pharmaceutical, Inc. (NasdaqGS: COLL). Under the terms of the proposed transaction, shareholders of BioDelivery will receive only $5.60 in cash for each share of BioDelivery that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration underval
Feb 15, 2022 05:47 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BioDelivery Sciences International, Inc. (Nasdaq - BDSI), Zurn Water Solutions Corporation (NYSE - ZWS), Edoc A
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or financial obligation to you. BioDelivery...
Feb 15, 2022 02:22 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.
NEW YORK, Feb. 15, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioDelivery Sciences International, Inc. ("BioDelivery" or the "Company") (NASDAQ: BDSI), in connection with the proposed acquisition of the Company by Collegium Pharmaceutical, Inc. ("Collegium") (NASDAQ: COLL) via a tender offer.  Under the terms of the acquisition agreement, the Company's shareholders will receive $5.60 in cash for each share of BioDelivery common stock that they hold.  The transaction is valued at approximately
Feb 14, 2022 12:20 pm ET
BIODELIVERY SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BDSI and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (“BDSI”) breached their fiduciary...
Feb 14, 2022 06:30 am ET
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. BDSI has a portfolio of...
Feb 14, 2022 06:30 am ET
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it has entered into a definitive merger agreement for...
Feb 10, 2022 04:01 pm ET
Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022, at 4:30 p.m. Eastern Time. The Company will discuss its fourth quarter and full-year...
Dec 28, 2021 08:00 am ET
Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the execution of a settlement framework to resolve all 27 pending opioid-related...
Dec 06, 2021 09:29 am ET
Collegium Ranks as a Top Place to Work for 2021 by The Boston Globe
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of the Top Places to Work in Massachusetts in The Boston...
Nov 15, 2021 08:30 am ET
Collegium Announces $25 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with...
Nov 11, 2021 04:01 pm ET
Collegium Participate in Upcoming Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences: Jefferies...
Nov 04, 2021 04:01 pm ET
Collegium Reports Third Quarter Fiscal 2021 Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the third quarter ended September 30, 2021 and provided a...
Oct 21, 2021 04:01 pm ET
Collegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today that the Company will host a conference call and live webcast on Thursday, November 4,...
Sep 13, 2021 08:00 am ET
Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its product portfolio were...
Sep 01, 2021 04:01 pm ET
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences during the month...
Aug 16, 2021 08:00 am ET
Collegium Announces $100 Million Share Repurchase Program
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors has authorized the repurchase of up to $100 million of the...
Aug 05, 2021 04:01 pm ET
Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate...
Jul 21, 2021 04:01 pm ET
Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
Jun 16, 2021 04:01 pm ET
Collegium Announces Publication of Real-World Data in Journal of Pain Research
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in...
May 20, 2021 04:05 pm ET
Collegium to Participate in Upcoming Investor Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference: Jefferies...
May 06, 2021 04:01 pm ET
Collegium Reports Record Quarterly Revenue of $87.7 Million
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate...
Apr 15, 2021 04:01 pm ET
Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
Feb 25, 2021 04:01 pm ET
Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the fourth quarter and year ended December 31, 2020 and...
Feb 11, 2021 04:01 pm ET
Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
Feb 08, 2021 05:49 pm ET
Monolithic Power Systems Set to Join S&P 500; Iridium Communications to Join S&P MidCap 400; Collegium Pharmaceutical to Join S&P SmallCap 600
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- S&P MidCap 400 constituent Monolithic Power Systems Inc. (NASD: MPWR) will replace TechnipFMC plc (NYSE: FTI) in the S&P 500, S&P SmallCap 600 constituent Iridium Communications Inc. (NASD: IRDM) will replace Monolithic Power Systems in the S&P MidCap 400, and Collegium Pharmaceutical Inc. (NASD: COLL) will replace Iridium Communications in the S&P SmallCap 600 effective prior to the opening of trading on Friday, February 12. TechnipFMC is being removed from the S&P 500 in anticipation of its announced spin-off of Technip Energie
Jan 06, 2021 04:01 pm ET
Collegium Provides 2021 Financial Guidance
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance. “Collegium achieved a financially...
Nov 05, 2020 04:01 pm ET
Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter ended September 30, 2020 and provided a corporate...
Oct 26, 2020 08:00 am ET
Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain Medicine
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Postmarketing Analysis of Misuse, Abuse and Diversion of Xtampza...
Oct 22, 2020 04:01 pm ET
Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
Sep 30, 2020 08:00 am ET
Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has reached a settlement agreement with Teva Pharmaceutical USA, Inc. (Teva)...
Sep 25, 2020 08:00 am ET
Collegium Appoints Rita Balice-Gordon to its Board of Directors
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Rita Balice-Gordon to its Board of Directors, effective September 24,...
Sep 14, 2020 08:00 am ET
Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio were...
Sep 09, 2020 04:05 pm ET
Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio will be...
Aug 05, 2020 04:01 pm ET
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the second quarter ended June 30, 2020 and provided a...
Jul 21, 2020 05:00 pm ET
Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
Jun 17, 2020 05:09 pm ET
Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best Places to Work. “We...
May 07, 2020 04:01 pm ET
Collegium Reports First Quarter 2020 Profitability
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the first quarter ended March 31, 2020 and provided a corporate...
Apr 23, 2020 04:01 pm ET
Collegium to Host Conference Call to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
Apr 07, 2020 04:01 pm ET
Collegium to Participate in Upcoming Investor Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in April: The...
Feb 27, 2020 04:01 pm ET
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the fourth quarter and year ended December 31, 2019 and...
Feb 26, 2020 01:05 pm ET
Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, confirmed today the details of the year-end earnings call, previously announced on February 13, 2020....
Feb 13, 2020 04:01 pm ET
Collegium Announces Closing of the Nucynta Franchise Acquisition
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today the closing of its previously announced acquisition of the Nucynta franchise from...
Feb 10, 2020 07:15 pm ET
Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities Act...
Feb 10, 2020 07:20 am ET
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a public offering registered...
Feb 06, 2020 04:01 pm ET
Collegium to Acquire U.S. Rights to Nucynta Franchise
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into a definitive agreement to acquire the U.S. rights to the...
Jan 07, 2020 04:05 pm ET
Collegium Provides 2020 Financial Guidance
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today provided full-year 2020 guidance for Xtampza® ER product revenues, Nucynta® franchise product...
Nov 26, 2019 08:01 am ET
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences in December: The...
Nov 08, 2019 08:00 am ET
Collegium to Participate in Upcoming Investor Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in November: The...
Nov 06, 2019 04:01 pm ET
Collegium Reports Third Quarter 2019 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter ended September 30, 2019 and provided a corporate...
Oct 23, 2019 08:00 am ET
Collegium to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
Sep 25, 2019 08:00 am ET
Collegium to Participate in Upcoming Investor Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in October: The...
Sep 03, 2019 04:01 pm ET
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences in September:...
Aug 29, 2019 04:01 pm ET
Collegium Announces Scientific Presentations at PAINWeek 2019 National Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations relating to rates of abuse and diversion of Xtampza® ER...
Aug 07, 2019 04:01 pm ET
Collegium Reports Second Quarter 2019 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter ended June 30, 2019 and provided a corporate...
Jul 24, 2019 04:01 pm ET
Collegium to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 7, 2019 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a...
May 29, 2019 08:00 am ET
Collegium to Present at Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in June: The...
May 08, 2019 04:01 pm ET
Collegium Reports First Quarter 2019 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the first quarter ended March 31, 2019 and provided a corporate...
Apr 30, 2019 04:01 pm ET
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences in May: The...
Apr 24, 2019 04:01 pm ET
Collegium to Host Conference Call to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a...
Apr 08, 2019 09:00 am ET
Market Trends Toward New Normal in Pareteum, Discovery Communications, Midstates Petroleum, Watsco, Collegium Pharmaceutical, and Cross Country Healthcare — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Pareteum Corp. (NASDAQ:TEUM), Discovery Communications, Inc. (NASDAQ:DISCK),...
Apr 02, 2019 08:00 am ET
Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut, M.D., as the company’s first Chief Medical Officer,...
Apr 01, 2019 08:00 am ET
Collegium to Present at Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in April: The H.C....
Feb 27, 2019 04:01 pm ET
Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the fourth quarter and year ended December 31, 2018 and...
Feb 13, 2019 08:40 am ET
Collegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, February 27, 2019 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide...
Jan 17, 2019 07:20 am ET
Report: Developing Opportunities within Enterprise Products Partners, Antero Midstream Partners LP, Integrated Device Technology, Collegium Pharmaceutical, GAIN Capital, and United Technologies — Futu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enterprise Products Partners L.P. (NYSE:EPD), Antero Midstream Partners LP...
Jan 07, 2019 08:00 am ET
Collegium Provides Full-Year 2019 Financial Guidance
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management today provided full-year 2019 guidance for Xtampza ER revenues, Nucynta Franchise revenues, and total...
Nov 12, 2018 07:24 am ET
Collegium to Present at Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain,...
Nov 08, 2018 04:05 pm ET
Collegium Reports Third Quarter Financial Results
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain,...
Oct 29, 2018 08:00 am ET
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER),” in the peer-reviewed medical journal, Journal of Opioid Management....
Oct 18, 2018 08:00 am ET
Report: Exploring Fundamental Drivers Behind Continental Building Products, Hornbeck Offshore Services, Digi International, Triple-S Management, Collegium Pharmaceutical, and Cardiovascular — New Hori
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Continental Building Products, Inc. (NYSE:CBPX), Hornbeck Offshore...
Oct 17, 2018 08:30 am ET
Collegium to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 8, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a...
Sep 28, 2018 02:16 pm ET
Collegium to Present at Upcoming Investor Conference
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will present at the following investor conference in October: The Cantor Global Healthcare Conference on Tuesday, October 2nd at 2:50 p.m. ET in New York City About...
Sep 04, 2018 10:01 am ET
Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas. The following posters will be presented...
Aug 24, 2018 07:30 am ET
Report: Exploring Fundamental Drivers Behind Fiesta Restaurant Group, Emerge Energy Services LP, Collegium Pharmaceutical, Cutera, Resources Connection, and Spark Therapeutics — New Horizons, Emerging
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fiesta Restaurant Group, Inc. (NASDAQ:FRGI), Emerge Energy Services LP...
Aug 08, 2018 04:01 pm ET
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the second quarter of 2018 and provided a corporate update.  “We made progress towards achieving our mission of becoming the leader in responsible pain...
Jul 20, 2018 01:06 pm ET
Collegium to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a...
Jul 10, 2018 07:30 am ET
Collegium Announces Promotion of Scott Dreyer to CCO
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, 2018. Mr. Dreyer brings over 25 years of commercial leadership...
Jun 18, 2018 07:40 am ET
New Research: Key Drivers of Growth for Outfront Media, Enel Chile, Banc of California, Northern Dynasty Minerals, Collegium Pharmaceutical, and Petroleo Brasileiro S.A. - Petrobras — Factors of Influ
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Outfront Media Inc. (NYSE:OUT), Enel Chile S.A. (NYSE:ENIC), Banc of...
Jun 04, 2018 04:01 pm ET
Collegium Announces CEO Succession
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that Joseph Ciaffoni, Executive Vice President and Chief Operating Officer at Collegium will be promoted to Chief Executive Officer and join the board of directors effective July 1,...
May 30, 2018 04:01 pm ET
Collegium to Present at Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: The Jefferies Global Healthcare Conference on Thursday, June 7th at 9:30 a.m. ET in New York CityThe William...
May 09, 2018 04:01 pm ET
Collegium Reports First Quarter Financial Results and Provides Corporate Update
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2018 and provided a corporate update.  “Our significant growth in the first quarter is a step forward in our evolution to becoming a leader...
May 02, 2018 04:01 pm ET
Collegium to Present at the Deutsche Bank Health Care Conference
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston. About Collegium...
Apr 23, 2018 07:45 am ET
Investor Expectations to Drive Momentum within WESCO International, Microchip Technology, Collegium Pharmaceutical, Actuant, Toro, and Expeditors International of Washington — Discovering Underlying F
NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of WESCO International, Inc. (NYSE:WCC), Microchip Technology...
Apr 20, 2018 08:01 am ET
Collegium to Host Conference Call to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass., April 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018 at 4:30 p.m. Eastern Time.  The Company...
Apr 04, 2018 04:01 pm ET
Collegium to Present at the H.C. Wainwright Global Life Sciences Conference
CANTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien...
Mar 19, 2018 08:00 am ET
Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel
CANTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018. Ms....
Mar 16, 2018 08:06 am ET
Collegium to Present at Upcoming Investor Conferences
CANTON, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March:
Mar 07, 2018 04:01 pm ET
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
CANTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update. 
Feb 26, 2018 04:01 pm ET
Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time.  The Company...
Feb 14, 2018 08:10 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Electronic Arts, The Goodyear Tire & Rubber, Wendy's, Collegium Pharmaceutical, IAC/InterActiveCorp, and Endurance International Gro
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Electronic Arts Inc. (NASDAQ:EA), The Goodyear...
Jan 10, 2018 09:01 am ET
Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise
CANTON, Mass., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has closed the transactions contemplated by its commercialization agreement (the “Agreement”) with Depomed, Inc. (“Depomed”) pursuant to which Collegium has the...
Dec 12, 2017 11:55 am ET
Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
CANTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will be hosting investor meetings at the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental...
Dec 04, 2017 04:30 pm ET
Collegium to License Rights to Commercialize Nucynta Franchise
CANTON, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has entered into a definitive commercialization agreement (the “Agreement”) with Depomed, Inc. (“Depomed”) pursuant to which Collegium will have the right to...
Nov 30, 2017 08:30 am ET
Detailed Research: Economic Perspectives on Electronic Arts, The Goodyear Tire & Rubber, Wendy's, Collegium Pharmaceutical, IAC/InterActiveCorp, and Endurance International Group — What Drives Growth
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Electronic Arts Inc. (NASDAQ:EA), The Goodyear...
Nov 22, 2017 08:42 am ET
Collegium to Present at the 29th Annual Piper Jaffray Healthcare Conference
CANTON, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that senior management will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference at 2:30pm ET on Tuesday, November 28,...
Nov 08, 2017 04:01 pm ET
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
CANTON, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2017 and provided a corporate update. 
Nov 07, 2017 08:30 am ET
Collegium Receives FDA Approval for sNDA for Xtampza® ER
Comparative OxyContin Data and Oral Human Abuse Deterrent Claim Added to Label
Nov 06, 2017 08:45 am ET
Collegium Notified that the FDA Will Not Meet PDUFA Goal Date for sNDA for Xtampza® ER
CANTON, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the U.S. Food and Drug Administration (FDA) will not meet the prescription drug user fee act (PDUFA) date for  its Supplemental New Drug...
Oct 30, 2017 04:01 pm ET
Collegium to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2017 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update....
Sep 06, 2017 07:00 am ET
Collegium to Present at Upcoming Investor Conferences
CANTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in September:...
Aug 09, 2017 04:01 pm ET
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Collegium strengthens leadership team with key additions to executive team and Board of DirectorsXtampza ER prescriptions grow by 34% in the second quarterXtampza ER Notice of Allowance granted and, once issued, will extend patent protection until 2036Well capitalized with $111.2 million in cash and cash equivalents Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the second quarter of 2017 and provided a corporate update. ...
Jul 18, 2017 04:01 pm ET
Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 9, 2017 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update....
Jun 08, 2017 04:01 pm ET
Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids
CANTON, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 2017 International Conference on Opioids taking place in Boston, MA....
May 30, 2017 04:10 pm ET
Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer
CANTON, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Joseph Ciaffoni to the newly created position of Executive Vice President and Chief Operating Officer, effective May 31, 2017....
May 10, 2017 04:01 pm ET
Collegium Reports First Quarter Financial Results and Provides Corporate Update
Xtampza® ER prescribed by more than 3,000 physicians since commercial launchXtampza ER Notice of Allowance granted and, once issued, will extend patent protection until 2030Well capitalized with $129.6 million in cash and cash equivalents Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2017 and provided a corporate update. ...
May 03, 2017 04:01 pm ET
Collegium to Host Conference Call to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update....
Apr 20, 2017 04:01 pm ET
Collegium to Present at the 42nd Annual Deutsche Bank Healthcare Conference
CANTON, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42nd Annual Deutsche Bank Healthcare Conference in Boston. The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the InterContinental Boston Hotel....
Apr 03, 2017 04:01 pm ET
Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients
CANTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a large national managed care organization with more than 3 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies.  Effective April 1, 2017, Xtampza ER is the exclusive branded oxycodone extended-release product for this organization’s Part D plan designs. This plan, along with previous formulary additions, continues to expand Xtampza ER’s total covered lives in the Medicare Part D channel....
Mar 28, 2017 04:01 pm ET
Collegium to Present at the 16th Annual Needham Healthcare Conference
CANTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 16th Annual Needham Healthcare Conference in New York City. The presentation will take place at 10:40 a.m. ET on Wednesday, April 5, 2017 at the Westin New York Grand Central Hotel....
Mar 09, 2017 04:01 pm ET
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
Xtampza® ER prescribed by more than 2,400 physicians since commercial launchONSOLIS® patent issued that extends patent protection until 2027Well capitalized with $153.2 million in cash and cash equivalents CANTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the fourth quarter of 2016 and provided a corporate update. ...
Feb 28, 2017 04:01 pm ET
Collegium to Host Conference Call to Discuss 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update....
Dec 15, 2016 08:56 am ET
Collegium Announces the Addition of Xtampza ER to Express Scripts’ Formulary
CANTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has finalized its contract with Express Scripts, the largest pharmacy benefits management (PBM) in the United States.  Pursuant to the contract, Xtampza ER is covered on the 2017 Express Scripts’ National Preferred Formulary. ...
Nov 21, 2016 08:01 am ET
Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal
CANTON, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that an independent review of Xtampza® ER has been published in the peer-reviewed medical journal, Drugs.  The review is titled “Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain” and highlights data pertaining to the efficacy, safety, abuse-deterrent properties, and alternative modes of administration of Xtampza ER. ...
Nov 11, 2016 04:01 pm ET
Collegium to Present at Upcoming Investor Conferences
CANTON, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in November:...
Nov 10, 2016 04:01 pm ET
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
Broadened Xtampza ER market access with commitments from large commercial payersSubmitted Supplemental New Drug Application to the FDASubmitted New Drug Submission to Health Canada CANTON, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2016 and provided a corporate update. ...
Nov 02, 2016 04:01 pm ET
Collegium to Host Conference Call to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 10, 2016 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update....
Oct 26, 2016 09:00 am ET
Collegium Prices Public Offering of $80 million of Common Stock
CANTON, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its previously announced public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share.  In addition, Collegium has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock offered in the public offering on the same terms and conditions.  The gross proceeds of this offering are expected to be $80 million, excluding underwriters’ discounts and commissions and any exercise of the ...
Oct 25, 2016 04:02 pm ET
Collegium Announces Proposed Public Offering of Common Stock
CANTON, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are being sold by Collegium.  In addition, Collegium has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering....
Oct 05, 2016 07:05 am ET
Collegium Submits Supplemental New Drug Submission to FDA for Xtampza® ER
CANTON, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) to enhance the label for Xtampza® ER (oxycodone extended-release), an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate....
Oct 03, 2016 09:00 am ET
Collegium Submits New Drug Submission to Health Canada for Xtampza® ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the submission of a New Drug Submission (NDS) to Health Canada seeking marketing approval of Xtampza® ER (oxycodone extended-release), an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate....
Sep 29, 2016 07:00 am ET
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
CANTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology....
Sep 09, 2016 08:30 am ET
Review of Xtampza® ER Published in The Journal of the American Medical Association
CANTON, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of an independent review of Xtampza® ER in The Journal of the American Medical Association (JAMA).  The review titled, “A New Abuse-Deterrent Opioid–Xtampza ER”, was previously published in The Medical Letter. ...
Sep 07, 2016 04:02 pm ET
Collegium to Present at the BioCentury NewsMakers Conference
CANTON, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 10:30 a.m. Eastern Time.  The conference will be held at Millennium Broadway Hotel, 145 West 44th Street, New York, NY....
Sep 06, 2016 07:00 am ET
Collegium Announces the Launch of OpioidIQ
CANTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announces the launch of OpioidIQ, an online educational tool to assist physicians and other healthcare providers with more effective pain management (Available at: www.OpioidIQ.com). The goal of OpioidIQ is to connect healthcare providers to information and resources aimed at supporting the safe and effective management of their patients with chronic pain who are appropriate for treatment with an opioid analgesic....
Sep 01, 2016 08:30 am ET
Collegium Announces Scientific Presentations at PAINWeek 2016 Meeting
CANTON, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2016 on September 8th in Las Vegas....
Aug 16, 2016 07:00 am ET
Collegium Announces Publication of Data on Alternative Modes of Administration of Xtampza ER
CANTON, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “An Abuse-Deterrent, Microsphere-in-Capsule Formulation of Extended-Release Oxycodone: Alternative Modes of Administration to Facilitate Pain Management in Patients with Dysphagia,” in the peer-reviewed medical journal, Current Medical Research and Opinion....
Aug 10, 2016 04:01 pm ET
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Received FDA approval for Xtampza® ER, Company’s lead opioid analgesic with abuse-deterrent propertiesAnnounced U.S. commercial launch of Xtampza ER Reported positive results from a clinical study comparing effect of physical manipulation of Xtampza ER with the abuse-deterrent version of OxyContin®Reported positive results from a clinical study evaluating Hydrocodone DETERx® as a second product candidateLicensed U.S. rights to commercialize ONSOLIS® (fentanyl buccal soluble film) from BioDelivery Sciences International CANTON, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceuti...
Aug 04, 2016 08:37 pm ET
Collegium to Host Conference Call to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 10, 2016 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update....
Aug 01, 2016 09:00 am ET
Collegium Receives European Patent Allowance Covering Xtampza® ER
CANTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL), a specialty pharmaceutical company focused on developing and commercializing innovative abuse-deterrent treatments for chronic pain and other diseases, announced that the European Patent Office has issued an intention to grant letter for European Patent Application No. 05759527.4, an application with claims covering Xtampza® (oxycodone) extended-release (ER) capsules. Xtampza ER is Collegium’s first product utilizing the DETERx® technology platform. Collegium currently has eight U.S. patents that...
Jul 06, 2016 04:15 pm ET
Collegium to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
CANTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 8 a.m. Eastern Time.  The conference will be held at Le Parker Meridian New York....
Jun 27, 2016 04:30 pm ET
Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year
CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of the Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Winners were selected by an independent panel of judges, and the award was pres...
Jun 22, 2016 08:00 am ET
Collegium Announces Positive Topline Results for Hydrocodone DETERx® Clinical Study
CANTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a clinical study evaluating Hydrocodone DETERx® as a second product candidate using its proprietary DETERx drug delivery technology platform. The objective of this pharmacokinetic proof of concept study was to assess two prospective formulations of Hydrocodone DETERx in a bioavailability clinical study. The primary goals were to assess the extended-release profile and the resistance to a common method of physical manipulation used by drug abusers – cru...
Jun 20, 2016 09:00 am ET
Collegium Announces Commercial Launch of Xtampza® ER
CANTON, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of Xtampza® ER (oxycodone) extended-release (ER) capsules in the United States. Xtampza ER was approved by the U.S. Food and Drug Administration (FDA) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate....
Jun 13, 2016 06:00 am ET
Collegium Announces Election of John A. Fallon, M.D. to Board of Directors
CANTON, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the election of John A. Fallon, M.D. to the Board of Directors....
Jun 02, 2016 04:05 pm ET
Collegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids
CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the International Conference on Opioids, which will be held in Boston on June 5-7, 2016....
Jun 02, 2016 10:36 am ET
Collegium to Present at Jefferies and William Blair Conferences
CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June:...
May 23, 2016 04:22 pm ET
Collegium Hosting Investor Day Event on May 25, 2016
CANTON, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) will host Investor Day on Wednesday, May 25th at the St. Regis Hotel in New York City (2 East 55th Street). The meeting will commence at 10:00am ET.  Parties interested in attending the event can Click Here to Register....
May 11, 2016 05:05 pm ET
BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
RALEIGH, N.C., May 11, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
May 11, 2016 04:05 pm ET
Collegium Licenses the U.S. rights to ONSOLIS® from BioDelivery Sciences
CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017....
May 11, 2016 06:00 am ET
Collegium Announces Poster Presentations for Xtampza™ ER at American Pain Society Meeting
CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza™ ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, in an elderly population at the American Pain Society Meeting, taking place May 11-14, 2016 in Austin, Texas....
May 10, 2016 04:05 pm ET
Collegium Reports First Quarter Financial Results and Provides Corporate Update
CANTON, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2016 and provided a corporate update. ...
May 04, 2016 07:00 am ET
Collegium Announces Positive Topline Results of Comparative Clinical Trial Evaluating the Effect of Crushing Xtampza™ ER Compared with OxyContin®
CANTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a comparative clinical trial evaluating the effect of physical manipulation by crushing of Xtampza™ ER (oxycodone extended-release capsules) compared with the abuse-deterrent version of OxyContin® (oxycodone hydrochloride extended-release tablets). Xtampza ER, Collegium’s first FDA approved product utilizing its proprietary DETERx® technology platform, is designed to maintain its ER pharmacokinetic (PK) profile after being subjected to common methods of...
Apr 27, 2016 10:08 am ET
Collegium to Host Conference Call to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2016 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update....
Apr 26, 2016 04:52 pm ET
Collegium Receives FDA Approval for Xtampza™ ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  ...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.